Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Extracellular matrix: new insights into its role in female reproductive aging and potential therapeutic strategies

Lu N., Wang J., Li YH., Fang XH., Peng YT., Luo QP.

Narrative Review on Hip, published in NPJ Aging (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
NPJ Aging (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41935057
PMCID
PMC13230844
DOI
10.1038/s41514-026-00371-z
Citations
1

Abstract (original English)

Extracellular matrix (ECM), once regarded as a passive structural scaffold, is now recognized as a key hallmark of aging. In the context of female reproductive aging, ECM remodeling acts as a pivotal driver of functional deterioration. This review outlines how age-associated ECM alterations, including collagen cross-linking, elastin degradation, and perturbed biomechanics, orchestrate ovarian aging through the mechanical activation of Hippo signaling, compromise endometrial receptivity via dysregulated matrix metalloproteinase activity, and impair embryo invasion by altering ligand presentation. We also discuss emerging ECM-targeted strategies, such as decellularized scaffolds, engineered hydrogels, and 3D-bioprinted matrices, which have demonstrated potential for rejuvenating reproductive function in preclinical models. Furthermore, matrisome-based biomarkers provide novel prognostic insights into reproductive outcomes. Collectively, these advances identify the ECM as a promising target for innovative, non-hormonal interventions aimed at extending female reproductive longevity.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research